DrugDashboards

Miglitol

Miglitol · MIGLITOL 100 mg/1 · Tablet, Coated · Oral · Westminster Pharmaceuticals, LLC

NDC 69367-0305-01 · 100 TABLET, COATED in 1 BOTTLE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.03per EAinvoice-surveyed acquisition cost · Aug 21, 2024
  • Part D plans paid (avg)$1.73per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$2.77per unitnegotiated price across 2,192 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$2.77per unit
middle half $2.32$2.89 · 2,192 plans · Apr 1, 2026
Est. net of rebates
≈ $2.77
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
40%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 93%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00May 2024Aug 2024$2.03
5 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$60.94
#90 count
$182.81

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA203965
TE code
Approval date
Feb 24, 2015
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Miglitol (Tablet, Coated)

LabelerStrengthFirst seenLast seen
Proficient Rx LPMIGLITOL 100 mg/1Jul 15, 2026Sep 2, 2026
Proficient Rx LPMIGLITOL 25 mg/1Jul 15, 2026Sep 2, 2026
Proficient Rx LPMIGLITOL 50 mg/1Jul 15, 2026Sep 2, 2026
Westminster Pharmaceuticals, LLCMIGLITOL 100 mg/1Jul 15, 2026Sep 2, 2026
Westminster Pharmaceuticals, LLCMIGLITOL 25 mg/1Jul 15, 2026Sep 2, 2026
Westminster Pharmaceuticals, LLCMIGLITOL 50 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Miglitol — NDC 69367-0305-01," retrieved September 3, 2026, https://drugdashboards.com/drug/69367030501.

Free to cite with attribution — see how the data is put together.